Perrottetinene-Like Compounds for Generalized Seizure Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing pharmaceutical compounds do not effectively address the needs for treating seizures and epilepsy, particularly in generalized and myoclonic seizure models.
Innovation Solution
Development and formulation of perrottetinene-like compounds, specifically CBD-PET and CBD-PET-OH, which are manufactured and tested for their potential pharmacological activity, particularly in treating seizures and epilepsy, utilizing a Lewis acid catalyst like zinc triflate for higher yields.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional pharmaceutical compounds are used, then existing treatment options are available, but they do not effectively address seizures and epilepsy in generalized and myoclonic seizure models
Solution Approach 1:
The patent modifies the chemical structure of perrottetinene by changing parameters such as the terpenoid moiety configuration, phenolic or resorcinol moiety substitution patterns, and phenylethyl arene side chain variations to create compounds with optimized anti-seizure activity across different seizure models including generalized and myoclonic types
Solution Approach 2:
The invention creates composite molecular structures combining specific terpenoid moieties with phenolic/resorcinol moieties and phenylethyl arene side chains to form perrottetinene-like compounds that exhibit enhanced and versatile anti-seizure properties not present in conventional single-structure pharmaceuticals
2Productivity
If traditional manufacturing methods are used, then standard production processes are available, but yields are lower compared to using Lewis acid catalysts
Solution Approach 1:
The patent introduces Lewis acid catalysts as intermediary substances to mediate the manufacturing process of perrottetinene-like compounds, enabling higher reaction yields and improved manufacturing efficiency without requiring fundamentally complex process changes
Solution Approach 2:
The invention optimizes manufacturing parameters by using Lewis acid catalysts to change the reaction conditions, achieving substantially greater yields of the desired compounds while maintaining process feasibility through well-established catalytic chemistry principles
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
CBD-PET and CBD-PET-OH exhibit statistically significant anti-seizure activity in animal models, showing effectiveness against clonic, tonic, and tonic-clonic seizures, with potential human doses ranging from 8 mg/Kg to 32 mg/Kg, suitable for various delivery routes.
Implementation Method 1
A method of manufacturing a perrottetinene-like compound comprising the steps of: reacting p Menthadienol with Dihydropinosylvin or Dihydroresvratrol in the presence of a Lewis acid, characterised in that the Lewis acid is zinc triflate.
Data Source
AI summary
The present disclosure describes terpenophenolic compounds and their use in medicine. The present disclosure further describes perrottetinene-like compounds, the manufacture thereof, formulations containing same and their use in medicine. Such compounds include (1′R, 2′R)-5′-methyl-phenethyl-2′-(prop-1-ene-2-yl)-1′, 2′, 3, 4′-tetrahydro-[1, 1-biphenyl]-2,6-diol (CBD-PET) or (1′R,2′R)-4-(4-hydroxyphenethyl)-5′-methyl-2′-(prop-1-ene-2-yl)-1′, 2′, 3, 4′-tetrahydro-[1, 1′-biphenyl]-2,6-diol (CBD-PET-OH).